Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Florbetapir-18 MNI 1126 (Primary)
- Indications Alzheimer's disease; Parkinson's disease
- Focus Diagnostic use
- Sponsors Invicro
- 06 Sep 2019 Planned End Date changed from 7 May 2019 to 7 May 2020.
- 06 Sep 2019 Planned primary completion date changed from 7 May 2019 to 7 May 2020.
- 24 Jul 2018 New trial record